Design Therapeutics/$DSGN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Design Therapeutics
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
- Ticker
- $DSGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 55
- Headquarters
- Carlsbad, United States
- Website
- www.designtx.com
DSGN Metrics
BasicAdvanced
$635M
-
-$1.18
1.64
-
Price and volume
Market cap
$635M
Beta
1.64
52-week high
$17.25
52-week low
$6.16
Average daily volume
489K
Financial strength
Current ratio
18.862
Quick ratio
18.61
Long term debt to equity
0.01
Total debt to equity
0.013
Profitability
EBITDA (TTM)
-78.344
Management effectiveness
Return on assets (TTM)
-22.53%
Return on equity (TTM)
-34.13%
Valuation
Price to book
3.15
Price to tangible book (TTM)
3.15
Price to free cash flow (TTM)
-11.029
Free cash flow yield (TTM)
-9.07%
Free cash flow per share (TTM)
-0.92
Growth
Earnings per share change (TTM)
5.59%
3-year earnings per share growth (CAGR)
-3.85%
What the Analysts think about DSGN
Analyst ratings (Buy, Hold, Sell) for Design Therapeutics stock.
Analyst projections of the future price of Design Therapeutics stock.
Bulls say / Bears say
DT-216P2 produced a promising early signal in Friedreich ataxia: after four weeks, the highest-dose cohort showed higher frataxin measures in blood and muscle alongside improvements in movement and fatigue scores. The drug was generally well tolerated, supporting further testing. (SEC)
The company had $207.4 million in cash and investments at the end of June 2026, which it said would cover anticipated needs for more than 12 months. That gives it room to advance clinical work before needing new funding. (SEC)
Design has moved beyond its lead programme: it has begun dosing patients in a Phase 1 trial of DT-818 for myotonic dystrophy type 1, while its Phase 2 DT-168 study for Fuchs dystrophy is ongoing. Positive results could show that the GeneTAC approach has value across more than one disease. (GlobeNewswire)
The encouraging clinical changes came from only four patients at the highest dose, after four weeks, in an early study. These exploratory results may not be sustained or reproduced in a larger, longer trial. (SEC)
The next-stage plan relies on blood frataxin as the primary efficacy measure, but the company is still seeking FDA feedback on whether it could support a faster approval route. If regulators do not accept that measure as a suitable surrogate, development may need to rely on clinical outcomes and take longer. (StockAnalysis)
The Fuchs dystrophy study’s data have slipped to 2027 because of a delay in supplies for the eye-drop formulation, while the first patient data from the myotonic dystrophy programme are also not expected until 2027. Those delays push back evidence for the company’s broader pipeline. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
DSGN Financial Performance
Revenues and expenses
DSGN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing DSGN
Fund name | Fund size | $DSGN weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.04% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.